PRICED Act

United States116th CongressHR-3379House of Representatives
Updated: Jun 21, 2019

Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.